ADHD Combination Treatment Addresses Memory Deficits Better than Mono Treatment

 ADHD in the News 2022-09-01


Based on brain activity, d-methylphenidate and guanfacine show promise as a combination treatment for attention deficit hyperactivity disorder (ADHD) in children, according to a study published in the Journal of the American Academy of Child & Adolescent Psychiatry.

View Article: Psychiatry Advisor, August 26, 2022




Other Articles in this Edition

Adderall is hard to find at some pharmacies following a labor shortage at the largest U.S. supplier

“Scary easy. Sketchy as hell.”: How startups are pushing Adderall on TikTok

Booming telehealth medicine is opening access to treatment for mental health: But surging prescriptions of stimulant drugs worry some

Attention Magazine February 2022 – CHADD

ADHD Combination Treatment Addresses Memory Deficits Better than Mono Treatment

Brain activity during sleep differs in young people with genetic risk of psychiatric disorders

Pediatric Patients With ADHD Show No Dual-Task Deficits

Military service has transgenerational impact, study shows

Adult ADHD diagnoses growing faster than kids’ cases

5 Smart Ways to Help College-Bound Students With ADHD Succeed

Unplanned Pregnancy, Sexual Health, and Adult ADHD

ADHD symptoms are more prevalent in male weightlifters who use steroids, study finds

“Celiac Fog” May Resemble ADHD, but Celiac Disease Doesn’t Raise ADHD Risk